Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market is expected to grow at a CAGR of 9.50% during the period 2025-2034. The prevalence is nearly 0.025% in general population. Asia has comparatively less incidence of AATD as compared to Europe or North American population. North America and Europe are likely to be key markets.

2024

Base Year

2018-2024

Historical Period

2025-2034

Forecast Period

Compound Annual Growth Rate

9.5%

Value in USD Million

2025-2034


Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Outlook

*this image is indicative*

Global Market Likely to be Driven by Advantages Offered by the Need to Effectively Treat Alpha-1 antitrypsin deficiency (AATD)

Alpha-1 antitrypsin deficiency (AATD) is a genetic illness, and may cause severe lung or liver disease. Symptoms may include trouble breathing and jaundiced, or yellow, skin.

Complications of Alpha-1 antitrypsin deficiency (AATD) depend on the disease it causes. These may include: lungs [if lung disease is developed, complications may include emphysema or bronchiectasis (damage to airway walls in the lungs)], liver (if liver disease is causes, symptoms may include swelling of abdomen and legs, higher risk of infections, or developing liver scarring or cancer), skin (in rare cases, a skin disease called panniculitis may develop; the condition may cause painful red lumps on the skin; the lumps may break open and release liquid or pus).

Augmentation therapy is the only particular therapy for alpha-1 antitrypsin deficiency (AATD); during the therapy, preparations of alpha-1 antitrypsin protein isolated from pooled blood of healthy donors are administered by way of weekly intravenous infusion. This raises the blood levels of alpha-1 antitrypsin deficiency AATD to levels protective for the lung. Studies report that augmentation therapy helps preserve lung function and reduces the number and severity of lung infections. While there is no cure for alpha-1 antitrypsin deficiency (AATD), the lung diseases that it causes can be treated. Treatment includes bronchodilators (enable easier breathing by relaxing the muscles surrounding the airways; short-acting bronchodilators last about four to six hours and are used as required; long-acting bronchodilators last twelve hours or more and may be used every day), inhaled corticosteroid medications (help decrease inflammation of the airways, enabling easy breathing), antibiotics, flu and pneumococcal vaccines, and surgery and other treatments (in advanced cases of disease, surgical options may be considered, such as lung volume reduction surgery and bullectomy). Along with treatment and medication, lifestyle changes may also be recommended, including exercise, training in managing the condition, and nutritional and psychological counselling.

Market Segmentation

The EMR’s report titled “Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

By product, the market is segmented into:

  • Bronchodilators
  • Oxygen Therapy
  • Augmentation Therapy
  • Corticosteroids

By route of administration, the market is classified into:

  • Injection
  • Oral
  • Inhalation

By application, the market is divided into:

  • Specialty Clinics
  • Hospitals
  • Pharmacies

By region, the market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Grifols, S.A.
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Kamada Ltd
  • Arrowhead Pharmaceuticals, Inc.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

An increased chance of developing chronic obstructive pulmonary disease (COPD), liver disease, skin issues (panniculitis), and blood vessel inflammation is associated with alpha-1 antitrypsin deficiency (AATD), a hereditary condition (vasculitis).

Most people could live good life with normal life expectancies, work, enjoy sports, and exercise with the right care. Damage to the liver and lungs might have symptoms and problems that can be treated medically.

The market is projected to grow at a CAGR of 9.50% between 2025 and 2034.

The major drivers of the market include the growing number of strategic collaboration, research and development activities, rising number of genetic tests, blood tests, and biopsy tests, rising initiatives by public and private organisations, and an increase in the prescription for combination therapies.

Growing geriatric population and rising healthcare expenditure are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The various products in the market are bronchodilators, oxygen therapy, augmentation therapy, and corticosteroids.

Based on route of administration, the market is classified into injection, oral, and inhalation.

The major applications of the market are speciality clinics, hospitals, and pharmacies.

Although there's no cure for AAT deficiency, but one can raise the amount of AAT protein in their blood, which protects the person against more lung damage. Doctors call this augmentation therapy.

The major players in the global Alpha-1 Antitrypsin Deficiency (AATD) treatment industry are Grifols, S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd, and Arrowhead Pharmaceuticals, Inc., among others.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2024
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Route of Administration
  • Application
  • Region
Breakup by Product
  • Bronchodilators
  • Oxygen Therapy
  • Augmentation Therapy
  • Corticosteroids
Breakup by Route of Administration
  • Injection
  • Oral
  • Inhalation
Breakup by Application
  • Specialty Clinics
  • Hospitals
  • Pharmacies
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Grifols, S.A.
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Kamada Ltd
  • Arrowhead Pharmaceuticals, Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

Single User License

10 % Off

USD

5,499

4,949

Datasheet

10 % Off

USD

3,299

2,969

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us